Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: A double-blind, randomized, placebo-controlled trial

Jee Yon Lee, Sang Hui Chu, Justin Y. Jeon, Mi Kyung Lee, Ji Hye Park, Duk Chul Lee, Ji Won Lee, Nam Kyu Kim

Research output: Contribution to journalArticle

39 Citations (Scopus)


Background: Probiotics may help resolve bowel symptoms and improve quality of life. We investigated the effects of 12 weeks of probiotics administration in colorectal cancer patients. Methods: We conducted a double-blind, randomized, placebo-controlled trial. The participants took probiotics (Lacidofil) or placebo twice a day for 12 weeks. The cancer-related quality of life (FACT), patient's health-9 (PHQ-9), and bowel symptom questionnaires were completed by each participant. Results: We obtained data for 32 participants in the placebo group and 28 participants in the probiotics group. The mean ages of total participants were 56.18 ± 8.86 years and 58.3% were male. Administration of probiotics significantly decreased the proportion of patients suffering from irritable bowel symptoms (0 week vs. 12 week; 67.9% vs. 45.7%, p = 0.03), improved colorectal cancer-related FACT (baseline vs. 12 weeks: 19.79 ± 4.66 vs. 21.18 ± 3.67, p = 0.04) and fatigue-related FACT (baseline vs. 12 weeks: 43.00 (36.50-45.50) vs. 44.50 (38.50-49.00), p = 0.02) and PHQ-9 scores (0 weeks vs. 12 weeks; 3.00 (0-8.00) vs. 1.00 (0-3.00), p = 0.01). We found significant differences in changes of the proportion of patients with bowel symptoms (p < 0.05), functional well-being scores (p = 0.04) and cancer-related FACT scores (p = 0.04) between the two groups. Conclusion: Probiotics improved bowel symptoms and quality of life in colorectal cancer survivors.

Original languageEnglish
Pages (from-to)1126-1132
Number of pages7
JournalDigestive and Liver Disease
Issue number12
Publication statusPublished - 2014 Jan 1


All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this